ViiV Healthcare announced Wednesday the latest findings from its EMBRACE phase 2b study. The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), kept viral levels suppressed in adults living with HIV who were already…
Continue reading...